Lung cancer is one of the most common — and deadliest — cancers. Small cell lung cancer makes up about 10 percent to 15 percent of all lung cancers. Because of early metastatic spread, small cell lung cancer has very poor long-term survival with less than 10 percent of patients surviving two years after diagnosis.
Chemotherapy is the most common treatment for small cell lung cancer and many consider drugs containing platinum the most effective agents. However, a new evidence review calls that assumption into question.